Aclaris Therapeutics (ACRS)
(Delayed Data from NSDQ)
$1.20 USD
+0.01 (0.84%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.19 -0.01 (-0.83%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACRS 1.20 +0.01(0.84%)
Will ACRS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACRS
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ACRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aclaris (ACRS) Upgraded to Buy: Here's Why
Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
Other News for ACRS
Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
Commit To Purchase Aclaris Therapeutics At $0.50, Earn 23.4% Annualized Using Options
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Analysts Offer Insights on Healthcare Companies: Connect Biopharma Holdings (CNTB), Aethlon Medical (AEMD) and Aclaris Therapeutics (ACRS)